The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy
Open accessAbstract
Diabetic nephropathy seems to occur as a result of an interaction of metabolic and haemodynamic factors. Glucose dependent pathways are activated within the diabetic kidney. These include increased oxidative stress, renal polyol formation and accumulation of advanced glycated end-products. Haemodynamic factors are also implicated in the pathogenesis of diabetic nephropathy and include increased systemic and intraglomerular pressure and activation of various vasoactive hormone pathways including the renin-angiotensin system and endothelin. These haemodynamic pathways, independently and with metabolic pathways, activate intracellular second messengers such as protein kinase C and MAP kinase, nuclear transcription factors such as NF-kappaB and various growth factors such as the prosclerotic cytokine, TGF-beta and the angiogenic, permeability enhancing growth factor, VEGF. These pathways ultimately lead to increased renal albumin permeability and extracellular matrix accumulation which results in increasing proteinuria, glomerulosclerosis and tubulointerstitial fibrosis. Therapeutic strategies involved in the management and prevention of diabetic nephropathy include currently available treatments such as intensified glycaemic control and antihypertensive agents, particularly those which interrupt the renin-angiotensin system. More novel strategies to influence vasoactive hormone action or to inhibit various metabolic pathways such as inhibitors of advanced glycation, specific protein kinase C isoforms and aldose reductase are at present under experimental and clinical investigation. It is predicted that multiple therapies will be required to reduce the progression of diabetic nephropathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DKD is considered to occur as a result of an interplay between metabolic and hemodynamic factors (58), with many of the putative pathways leading to injury having already been delineated (59).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [58]
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
Zatz, R., Dunn, B. R., Meyer, T. W., Anderson, S., Rennke, H. G., & Brenner, B. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112521 · Cited by 1,204
Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene
Mullins, J. J., Peters, J., & Ganten, D. (1990) · Nature · doi:10.1038/344541a0 · Cited by 919
Hostetter, T. H., Rennke, H. G., & Brenner, B. M. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90490-9 · Cited by 800
Zatz, R., Meyer, T. W., Rennke, H. G., & Brenner, B. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.17.5963 · Cited by 524
Role of angiotensin II in diabetic nephropathy
Leehey, D. J., Singh, A. K., Alavi, N., & Singh, R. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.07715.x · Cited by 273
Kelly, D. J., Wilkinson‐Berka, J. L., Allen, T. J., Cooper, M. E., & Skinner, S. L. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00019.x · Cited by 166
Self-citationAnimal models of spontaneous diabetic kidney disease
Velasquez, M. T., Kimmel, P. L., & Michaelis, O. E. (1990) · The FASEB Journal · doi:10.1096/fasebj.4.11.2199283 · Cited by 118
Kelly, D. J., Skinner, S. L., Gilbert, R. E., Cox, A. J., Cooper, M. E., & Wilkinson‐Berka, J. L. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00038.x · Cited by 103
Self-citation
Cited by
Sorted by citations
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Self-citationAdvanced Glycation End Products and Diabetic Complications
Singh, V. P., Bali, A., Singh, N., & Jaggi, A. S. (2014) · The Korean Journal of Physiology & Pharmacology · doi:10.4196/kjpp.2014.18.1.1 · Cited by 1,518
Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy
Navarro‐González, J. F., Fernández, C. M., de Fuentes, M. M., & García-Pérez, J. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.51 · Cited by 1,073
Extracellular Matrix Metabolism in Diabetic Nephropathy
Mason, R. M., & Wahab, N. A. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065640.77499.d7 · Cited by 658
Renal Autoregulation in Health and Disease
Carlström, M., Wilcox, C. S., & Arendshorst, W. J. (2015) · Physiological Reviews · doi:10.1152/physrev.00042.2012 · Cited by 485
Metadata
- Authors
- Cooper, M. E.
- Affiliations
- The University of Melbourne (AU)
- Corresponding author
- Cooper, M. E.
- ORCID
- Cooper, M. E.
- Venue
- Diabetologia
- Published
- 2001-11-01
- Volume
- 44
- Issue
- 11
- Pages
- 1957-1972
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1991427290
- Cited by
- 375
- References
- 14
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 10 · 2023: 14 · 2022: 5 · 2021: 19 · 2020: 16 · 2019: 9 · 2018: 8 · 2017: 15 · 2016: 13 · 2015: 10 · 2014: 23 · 2013: 20 · 2012: 14
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kidney Health Australia
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- diabetic nephropathy, metabolic factors, oxidative stress, advanced glycation end products, intraglomerular pressure, renin-angiotensin system, endothelin, protein kinase C, mitogen-activated protein kinase, NF-κB, TGF-beta, vascular endothelial growth factor, albumin permeability, extracellular matrix accumulation, glomerulosclerosis, tubulointerstitial fibrosis, proteinuria, aldose reductase inhibitors, renin-angiotensin system inhibitors, antihypertensive therapy, glycemic control, pathogenesis
- MeSH terms
- Animals, Diabetic Nephropathies, Diabetic Retinopathy, Disease Models, Animal, Hemodynamics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
